SOUTH SAN FRANCISCO, Calif., March 10, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON), today announced the issuance of U.S. patent 7,887,836 B2, which covers compositions and methods for treating lymphoma, leukemia and myeloma for Marqibo (vincristine sulfate liposome injection). The patent expires in March 2020. A previously issued patent covers Marqibo's use for treating relapsed acute lymphoblastic leukemia (ALL).
New Patent Issued For Talon Therapeutics' Marqibo(R) Expands Disease Coverage To Include Lymphoma, Leukemia And Myeloma
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.